91 results on '"Hansen, John‐Bjarne"'
Search Results
2. Proportion of venous thromboembolism attributed to recognized prothrombotic genotypes in men and women
3. Galectin-3-binding protein and future venous thromboembolism
4. Extracellular vesicles from activated platelets possess a phospholipid-rich biomolecular profile and enhance prothrombinase activity
5. “C1-inhibitor levels and Venous Thromboembolism: Results from a Mendelian Randomization Study”: comment from Grover et al
6. “High plasma levels of C1-inhibitor are associated with lower risk of future venous thromboembolism”: reply
7. Combined effect of high factor VIII levels and high mean platelet volume on the risk of future incident venous thromboembolism
8. Plasma levels of P-selectin and future risk of incident venous thromboembolism
9. High plasma levels of C1-inhibitor are associated with lower risk of future venous thromboembolism
10. Hand grip strength in venous thromboembolism: risk of recurrence and mortality
11. Venous thromboembolism and risk of depression: a population-based cohort study
12. VTE epidemiology and challenges for VTE prevention at the population level
13. Complement factors B, D, C3bBbP and risk of future venous thromboembolism
14. Low D-dimer levels at diagnosis of venous thromboembolism are associated with reduced risk of recurrence: data from the TROLL registry
15. Impact of the von Willebrand factor-ADAMTS13 axis on the risk of future venous thromboembolism
16. Redefining clinical venous thromboembolism phenotypes: a novel approach using latent class analysis
17. Hand grip strength and risk of incident venous thromboembolism: The Tromsø study
18. Joint effect of myocardial infarction and obesity on the risk of venous thromboembolism: The Tromsø Study
19. Risk factors and predictors for venous thromboembolism in people with ischemic stroke: A systematic review
20. Management of bleeding risk in patients who receive anticoagulant therapy for venous thromboembolism: Communication from the ISTH SSC Subcommittee on Predictive and Diagnostic Variables in Thrombotic Disease
21. A systematic review of biomarkers among hospitalized patients with COVID‐19 predictive of venous thromboembolism: A communication from the Predictive and Diagnostic Variables Scientific and Standardization Committee of the ISTH
22. Elevated plasma levels of plasminogen activator inhibitor‐1 are associated with risk of future incident venous thromboembolism
23. Multi‐phenotype analyses of hemostatic traits with cardiovascular events reveal novel genetic associations
24. Plasma levels of platelet‐derived microvesicles are associated with risk of future venous thromboembolism
25. Rosuvastatin treatment decreases plasma procoagulant phospholipid activity after a VTE: A randomized controlled trial
26. A rapid, sensitive, and specific assay to measure TF activity based on chromogenic determination of thrombin generation
27. Effect of lower‐leg trauma and knee arthroscopy on procoagulant phospholipid‐dependent activity
28. Socioeconomic status and risk of incident venous thromboembolism
29. Plasma procoagulant phospholipid clotting time and venous thromboembolism risk
30. Elevated plasma D-dimer levels are associated with risk of future incident venous thromboembolism
31. Prothrombotic genotypes and risk of venous thromboembolism in occult cancer
32. Hemostatic factors, inflammatory markers, and risk of incident venous thromboembolism: The Multi‐Ethnic Study of Atherosclerosis
33. Development and implementation of common data elements for venous thromboembolism research: on behalf of SSC Subcommittee on official Communication from the SSC of the ISTH
34. Combined effects of five prothrombotic genotypes and cancer on the risk of a first venous thromboembolic event
35. Atrial fibrillation, venous thromboembolism, ischemic stroke, and all‐cause mortality: The Tromsø study
36. Prothrombotic genotypes and risk of major bleeding in patients with incident venous thromboembolism
37. D-dimer as a stand-alone test to rule out deep vein thrombosis
38. Myocardial infarction, prothrombotic genotypes, and venous thrombosis risk: The Tromsø Study
39. Impact of respiratory symptoms and oxygen saturation on the risk of incident venous thromboembolism—the Tromsø study
40. Initiation of statins and risk of venous thromboembolism: Population-based matched cohort study
41. Cardiorespiratory fitness and future risk of venous thromboembolism
42. Plasma levels of mannose‐binding lectin and future risk of venous thromboembolism
43. Impact of prothrombotic genotypes on the association between family history of myocardial infarction and venous thromboembolism
44. Complement activation assessed by the plasma terminal complement complex and future risk of venous thromboembolism
45. Physical activity and risk of recurrence and mortality after incident venous thromboembolism
46. Effect of prothrombotic genotypes on the risk of venous thromboembolism in patients with and without ischemic stroke. The Tromsø Study
47. Hospitalization as a trigger for venous thromboembolism – Results from a population-based case-crossover study
48. Dietary intake of marine n‐3 polyunsaturated fatty acids and future risk of venous thromboembolism
49. Associations between complement pathways activity, mannose-binding lectin, and odds of unprovoked venous thromboembolism
50. Prothrombotic genotypes and risk of venous thromboembolism in cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.